Clinicopathologic correlations in leukemia cutis

Su, W.P. Daniel; Buechner, S. A.; Li, Chin-Yang

doi:10.1016/s0190-9622(84)70145-9

Cited by 177 publications

(27 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chronic lymphocytic leukemia (CLL) is a low-grade clonal B-lineage lymphoid neoplasm that can occasionally involve the skin with specific lesions, most often as papules, plaques, nodules, or large tumors. Erythroderma may also occur [10,11,12]. …”

Section: Introductionmentioning

confidence: 99%

Sézary Syndrome Coexisting with B-Cell Chronic Lymphocytic Leukemia: Case Report and Review of the Literature

et al. 2007

View full text Add to dashboard Cite

Introduction: The simultaneous presentation of chronic B-cell lymphocytic leukemia (B-CLL) and cutaneous T-cell lymphoma (CTCL) is extremely rare. Case Report: We describe a patient with B-CLL and Sézary syndrome (SS), an erythrodermic and leukemic variant of CTCL. Despite treatment, the SS progressed to involve internal organs and eventual death of the patient from sepsis. This is the first reported case of SS coexisting with chronic lymphocytic leukemia in which an anti-Vβ13.6 antibody was used to serially track changes in circulating neoplastic T cells vis-à-vis neoplastic B cells and to detect neoplastic T cells in ascitic fluid near the end of the patient’s life. Discussion: We speculate that the coexistence of B-CLL and CTCL is the result of an initiating genetic or epigenetic defect at the level of the common lymphoid stem cell that predisposes both B-cell and T-cell lineages to additional oncogenic changes at a more advanced stage of differentiation.

show abstract

Section: Introductionmentioning

confidence: 99%

Sézary Syndrome Coexisting with B-Cell Chronic Lymphocytic Leukemia: Case Report and Review of the Literature

et al. 2007

View full text Add to dashboard Cite

show abstract

“…As many as 90% of patients with LC have been reported to have other extramedullary involvement 3 of sites such as the central nervous system, orbita, and ovaries. 3,4 Moreover, in 1984, Su et al 5 and Su 6 reported that 88% of patients with LC die within 1 year of the diagnosis. However, recent literature has been more equivocal about the association of LC with prognosis.…”

mentioning

confidence: 99%

Association of Leukemia Cutis With Survival in Acute Myeloid Leukemia

2019

View full text Add to dashboard Cite

IMPORTANCE Leukemia cutis (LC) is an important yet understudied extramedullary manifestation of leukemia. Previous reports have suggested poor prognosis for patients with LC, but these reports have largely consisted of descriptive studies with a limited number of patients. OBJECTIVES To identify patient factors associated with LC and characterize the association of LC with the course of acute myeloid leukemia (AML). DESIGN, SETTING, AND PARTICIPANTS This retrospective, matched-cohort study included 1683 patients with AML diagnosed from January 1, 2005, to April 1, 2017, with and without biopsy-proven LC seen at a single-center, tertiary care hospital in St Louis, Missouri. To specifically evaluate differences in survival, propensity scoring was used to match patients with AML with LC to patients with AML without LC off the logit of propensity score based on age, race/ethnicity, sex, and leukemia type. Kaplan-Meier methods were used to compare cumulative probability survival. Matched survival analysis was performed with extended Cox regression to determine factors associated with leukemia-specific and overall survival. MAIN OUTCOMES AND MEASURES Leukemia-specific survival and overall survival. RESULTS A total of 1683 patients were reviewed, including 78 patients with biopsy-proven LC of the AML type and 1605 patients with AML without LC. A total of 62 of the patients with AML and LC (mean [SD] age, 58.2 [11.7] years; 33 [53.2%] male) were matched in a 1:3 ratio to 186 patients with AML without LC (mean [SD] age, 58.2 [13.5] years; 103 [55.4%] male). The 5-year survival among the 62 patients with AML with LC was 8.6%, shorter than the 28.3% among the 186 matched patients with AML without LC. Matched survival analysis revealed that patients with AML and LC compared with those without LC had hazard ratios of 2.06 (95% CI, 1.26-3.38; P = .004) for leukemia-specific death and of 1.66 (95% CI, 1.06-2.60; P = .03) for all-cause death. In addition, matched patients with LC had greater odds of extramedullary organ burden (odds ratio, 3.48; 95% CI, 1.72-7.05; P < .001). CONCLUSIONS AND RELEVANCE The results suggest that the presentation of LC in patients with AML is associated with decreased overall survival and leukemia-specific survival. Patients with AML presenting with LC may require more intensive treatment and monitoring of their leukemic disease.

show abstract

“…1 Patients with such transformation may then develop specific cutaneous involvement (leukaemia cutis), in which the skin becomes infiltrated by malignant haemopoietic cells. 2 However, nonspecific cutaneous lesions, which do not contain a malignant infiltrate, are more common, and include cutaneous infections and a spectrum of neutrophilic dermatoses such as dermal vasculitis, pyoderma gangrenosum and Sweet’s syndrome.…”

mentioning

confidence: 99%